#aging research

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

První lidé, kteří užili Dasatinib + Quercetin: Co 14‑osobná pilotní studie s IPF ukázala (a neukázala)

BY DR. SYNAPSE · 15. 10. 2026

V roce 2019 výzkumníci poprvé zaznamenali, že lidé s idiopatickou plicní fibrózou (IPF) užili senolitickou kombinaci dasatinibu a quercetinu. Po tří‑týdenním intermitentním cyklu se u účastníků projevil výrazný pokrok ve 6‑minutové chůzi, rychlosti chůze a čase vstávání z židle, i když plicní funkce zůstala nezměněna. Studie zaznamenala jeden vážný nežádoucí účinek a časté dýchací, kožní i gastrointestinální obtíže. Jedná se o otevřenou, nekontrolovanou studii s onkologickým lékem spárovaným s farmakologickou dávkou flavonoidu, ne o suplementační protokol.